Increased seroreactivity to human T cell lymphoma/leukemia virus-related endogenous sequence-1 gag peptides in patients with human T cell lymphoma/leukemia virus myelopathy

AIDS Research and Human Retroviruses

Volumn 31, Issue 2, 2015, Pages 242-249

  Perzova, Raisa ^a   Graziano, Elliot ^a   Sanghi, Swathi ^a   Welch, Caitlin ^a   Benz, Patricia ^a   Abbott, Lynn ^a   Lalone, Danielle ^a   Glaser, Jordan ^b   Loughran, Thomas ^c   Sheremata, William ^d   Poiesz, Bernard J ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; VIRUS ANTIBODY; VIRUS DNA; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; BLOOD DONOR; CROSS REACTION; DEGENERATIVE DISEASE; ENDOGENOUS RETROVIRUS; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMIA VIRUS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROLOGY; SPINAL CORD DISEASE; T CELL LEUKEMIA; T CELL LYMPHOMA; VOLUNTEER; BLOOD; CHEMISTRY; DNA SEQUENCE; GENETICS; HUMAN T-LYMPHOTROPIC VIRUS 1; IMMUNOLOGY; MOLECULAR GENETICS; TROPICAL SPASTIC PARAPARESIS;

ANTIBODIES, VIRAL; BLOOD DONORS; CROSS REACTIONS; DNA, VIRAL; ENDOGENOUS RETROVIRUSES; GENE PRODUCTS, GAG; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MOLECULAR SEQUENCE DATA; PARAPARESIS, TROPICAL SPASTIC; RETROVIRIDAE PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84923218172     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0171     Document Type: Article

References (54)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, and Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-7419.
2. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoski I, Golde D, and Gallo RC: A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;281:4571-4573.
3. Gessain A, Barin F, Vernant JC, et al.: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-409.
4. Hjelle B, Appenzeller O, Mills R, et al.: Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992;339:645-646.
5. Kaplan JE, Osame M, Kubota H, et al.: The risk of development of HTLV-I-Associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3:1096-1101.
6. Orland JR, Engstrom J, Friday J, et al.: Prevalence and clinical features of HTLV neurologic disease in the HTLV outcomes study. Neurology 2003;61:1588-1594.
7. Thomas A, Perzova R, Abbott L, et al.: LGL leukemia and HTLV. AIDS Res Hum Retroviruses 2010;26:33-40.
8. Loughran TP Jr, Hadlock KG, Perzova R, et al.: Epitope mapping of HTLV envelope seroreactivity in LGL leukemia. Br J Haematol 1998;101:318-324.
9. Perzova R, Graziano E, Sanghi S, et al.: Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy. Virol J 2013;10:360.
10. Toufaily C, Landry S, Leib-Mosch C, Rassart E, and Barbeau B: Activation of LTRs from different human endogenous retrovirus (HERV) families by the HTLV-1 tax protein and T-cell activators. Viruses 2011;3:2146-2159.
11. Perl A, Rosenblatt JD, Chen IS, et al.: Detection and cloning of new HTLV-related endogenous sequences in man. Nucl Acids Res 1989;17:6841-6854.
12. Perl A, Issacs CM. Eddy RL, et al.: The human T-cell leukemia virus-related endogenous sequence (HRES-1) is located on chromosome 1 at q42. Genomics 1991;11:1172-1173.
13. Rasmussen HG, Christensen K, and Clausen J: Sequencing and detection of polymorphisms in the 5¢ end of the human endogenous retroviral element, HRES-1. Dis Markers 1996;13:1-9.
14. Pullman R Jr, Bonilla E, Phillips PE, Middleton GA, and Perl A: Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus.Arthritis Rheum2008;58:532-540.
15. Rasmussen HB and Clausen J: A novel haplotype of the endogenous retrovirus, HRES-1, in patients with multiple sclerosis and health individuals. Autoimmunity 1999;29: 141-145.
16. Lefranc D, Dubucquoi S, Almeras L, et al.: Molecular analysis of endogenous retrovirus HRES-1: Identification of frameshift mutations in region encoding putative 28-kDa autoantigen. Biochem Biophys Res Commun 2001;283: 437-444.
17. Banki K, Maceda J, Hurley E, et al.: Human T-cell lymphotropic virus (HTLV)-related endogenous sequence, HRES-1, encodes a 28-kDa protein: A possible autoantigen for HTLV-I gag-reactive autoantibodies. Proc Natl Acad Sci USA 1992;89:1939-1943.
18. Sokol L and Loughran TP Jr: Large granular lymphocyte leukemia. Oncologist 2006;11:263-273.
19. WHO: Virus diseases: Human T-lymphotropic virus type I (HTLV-I). Wkly Epidemiol Rec 1989;64:382.
20. Lezin A, Olindo S, Oliere S, et al.: Human T-lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: A new criterion for the diagnosis of HTLV-I-Associated myelopathy/tropical spastic paraparesis?. J Infect Dis 2005;191:1830-1834.
21. Polman CH, Reingold SC, Banwell B, et al.: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
22. Loughran TP Jr, Coyle T, Sherman MP, et al.: Detection of human T-cell leukemia/lymphoma virus, type II, in a patient with large granular lymphocyte leukemia. Blood 1992;80:1116-1119.
23. Lipka JJ, Miyoski I, Hadlock KG, et al.: Segregation of human T cell lymphotropic virus type I and II infections by antibody reactivity to unique viral epitopes. J Infect Dis 1992;165:268-272.
24. Ehrlich GD, Glaser JB, LaVigne K, et al.: Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: Type-specific identification of HTLVs by polymerase chain reaction. Blood 1998;74:1658-1664.
25. Dube S, Dolcini G, Abbott L, et al.: The complete genomic sequence of a BLV strain from Holstein cow from Argentina. Virology 2000;277:79-86.
26. Altschul SF, Gish W, Miller W, Myers EW, and Lipman DJ: Basic alignment search tool. J Mol Biol 1990;215:403-410.
27. Kirkman TW: Statistics to use 1996. www.physics.csbsju.edu/stats/.(17 October 2013
28. Yamano Y, Nagai M, Brennan, et al.: Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8( + ) T cells, and disease severity in HTLV-1-Associated myelopathy (HAM/.TSP). Blood 2002;99:88-94.
29. Yoshida M, Osame M, Kawai H, et al.: Increased replication of HTLV-I in HTLV-I-Associated myelopathy. Ann Neurol 1989;26:331-335.
30. Sabouri AH, Saito M, Lloyd AL, et al.: Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-Associated myelopathy/tropical spastic paraparesis. J Infect Dis 2004;190:1279-1285.
31. Trevino A, Lopez M, Vispo E, et al.: Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin Infect Dis 2012;55:e1-4.
32. Sabouri AH, Usuku K, Hajashi D, et al.: Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8 + T cells in HTLV-1 associated neurologic disease. Blood 2008;112:2411-2420.
33. Jeffrey KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, and Procter J: HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-Associated myelopathy. Proc Natl Acad Sci USA 1999;96:3848-3853.
34. Bhagavati S, Ehrlich G, Kula RW, et al.: Detection of human T-cell lymphoma/leukemia virus type I DNA and antigen in spinal fluid and blood of patients with chronic progressive myelopathy (HAM/TSP). N Engl J Med 1988;318:1141-1147.
35. Harrington WJ, Sheremata W, Hjelle B, et al.: Spastic ataxia associated with human T-cell lymphotropic virus type II infection. Ann Neurol 1993;33:441-444.
36. Kalume F, Lee SM, Marcos Y, Callaway JC, and Levin MC: Molecular mimicry: Cross reactive antibodies from patients with immune-mediated neurologic disease inhibit neuronal firing. J Neurosci Res 2004;77:82-89.
37. Lender ES, Linton LM, Birren B, et al.: Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
38. Depil S, Roche C, Dussart P, and Prin L: Expression of human endogenous retrovirus HERV-K, in the blood cells of leukemia patients. Leukemia 2002;16:254-259.
39. Morgan D and Brodsky I: Human endogenous retrovirus (HERV-K) particles in megakaryocytes cultured from essential thrombocythemia peripheral blood stem cells. Exp Hematol 2004;32:520-525.
40. Nakagawa K, Brusic V, McCall G, and Harrison LC: Direct evidence for the expression of multiple endogenous retrovirus class II-like sequences. J Gen Virol 1999;80:255-260.
41. Herve CA, Lugli EB, Brand A, Griffiths DJ, and Venables PJ: Autoantibodies to human endogenous retrovirus K are frequently detected in health and disease and react with multiple epitopes. Clin Exp Immunol 2002;128:75-87.
42. Andersson ML, Lindeskog M, Medstrand P, Westley B, May F, and Bloomberg J: Diversity of human endogenous retrovirus class II-like sequences. J Gen Virol 1999;80:255-260.
43. Flockerzi A, Ruggieri A, Frank O, et al.: Expression patterns of transcribed human endogenous retrovirus HERV-K (HML-2) loci in human tissues and the need for a HERV transcriptome project. BMC Genom 2008;9:354.
44. Jones RB, Leal FE, Hasenkrug AM, et al.: Human endogenous retrovirus K (HML-2) Gag and Env specific T-cells responses are not detected in HTLV-I-infected subjects using standard peptide screening methods. J Negat Results Biomed 2013;12:3.
45. Garrison KE, Jones RB, Meikejohn DA, et al.: T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog 2007;3:e165.
46. SenGupta D, Tandon R, Vieria RG, et al.: Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol 2011;85:6977-6985.
47. Tandon R, SenGupta D, Nahlovu C, et al.: Identification of human endogenous retrovirus specific T-cell responses in vertically HIV-1 infected subjects. J Virol 2011;85:11526-11531.
48. Frank O, Verbeke C, Schwarz N, et al.: Variable transcriptional activity of endogenous retroviruses in human breast cancer. J Virol 2008;82:1808-1818.
49. Contreras-Galindo R, Kaplan MH, Leissner P, et al.: Human endogenous retrovirus K (HML-2) elements in plasma of people with lymphoma and breast cancer. J Virol 2008;82:9329-9336.
50. Freimanis G, Hooley P, Ejtehadi HD, et al.: A role for human endogenous retrovirus-K (HML-2) elements in rheumatoid arthritis: Investigating mechanisms of pathogenesis. Clin Exp Immunol 2010;160:340-347.
51. Tristem M: Identification and characterization of novel human endogenous retrovirus families by phylogenetic screening of the human genome mapping project database. J Virol 2000;74:3715-3730.
52. Nelson PN, Carnegie PR, Martin J, et al.: Demystified. Human endogenous retroviruses. J Clin Pathol Mol Pathol 2003;56:11-18.
53. Brookes SM, Pandolfino YA, Mitchell TJ, et al.: The immune response to and expression of cross-reactive retroviral GAG sequences in autoimmune disease. Br J Rheum 1992;31:735-742.
54. Perl A, Colombo E, Dai H, et al.: Antibody reactivity to the HRES-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes. Correlation with antinuclear antibodies and HLA class II alleles. Arthritis Rheum 1995;38:735-742.